Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Incyte Corp. (NASDAQ: INCY).

Full DD Report for INCY

You must become a subscriber to view this report.

Recent News from (NASDAQ: INCY)

Today's Research Reports on Trending Tickers: Incyte and Supernus Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial Average jumped 1.13 percent to close at 25,826.43, while the S&P 500 Index inc...
Date: December, 04 2018 08:00
Incyte's Jakafi successful in mid-stage GvHD study; shares up 7%
A Phase 2 clinical trial, REACH1 , evaluating Incyte's ( INCY +6.5% ) Jakafi (ruxolitinib), combined with corticosteroids, in patients with acute graft-versus-host disease (GvHD) who failed to respond adequately to corticosteroids met the primary endpoint . The results were presented at ...
Source: SeekingAlpha
Date: December, 03 2018 12:30
Results of REACH1 Study of Ruxolitinib (Jakafi®) for the Treatment of Acute Graft-Versus-Host Disease Demonstrate Rapid and Durable Patient Benefit
Updated data to be presented today at the 60 th annual ASH meeting REACH1 study formed the basis of sNDA, now under Priority Review by the FDA Incyte Corporation (Nasdaq:INCY) announces updated results from its pivotal Phase 2 REACH1 study evaluating ruxolitinib (Jaka...
Source: Business Wire
Date: December, 03 2018 10:00
Incyte to Present at Upcoming Investor Conference
Incyte Corporation (Nasdaq:INCY) announced today that it will present at Evercore ISI HEALTHCONx on Wednesday, November 28, 2018 at 3:30 pm EST in Boston. The presentation will be webcast live and can be accessed at in the Investors section under “Events and Prese...
Source: Business Wire
Date: November, 07 2018 08:00
Healthcare And Biotechnology Dashboard - Update
This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued regarding historical averages, but profitability measu...
Source: SeekingAlpha
Date: November, 06 2018 11:32
Factors of Influence in 2018, Key Indicators and Opportunity within Molson Coors Brewing, Coca-Cola European Partners, Brinker International, Incyte, RPC, and Group 1 Automotive - New Research Emphasizes Economic Growth
NEW YORK, Nov. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Molson Coors Brewing Company (NYSE:TAP), Coca-Cola European Partners PLC ...
Source: GlobeNewswire
Date: November, 05 2018 07:35
Multiple Abstracts Highlighting Data from Incyte's Targeted Therapy Portfolio Accepted for Presentation at the 60th Annual ASH Meeting
Results of REACH1 trial evaluating ruxolitinib (Jakafi ® ) in patients with steroid-refractory acute graft-versus-host disease (GVHD) accepted as an oral presentation Incyte (Nasdaq:INCY) announces that multiple abstracts, including data from its clinical development programs...
Source: Business Wire
Date: November, 01 2018 10:36
Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Incyte
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / U.S. equities rose on Wednesday as a number of high profile companies reported upbeat corporate earnings that helped boost investor confidence. The Dow Jones Industrial Average gained 0.97 percent to close at 25,115.76, while the S&P 500 In...
Date: November, 01 2018 08:00
Incyte (INCY) Q3 2018 Results - Earnings Call Transcript
Incyte Corp. (INCY) Q3 2018 Earnings Call October 30, 2018 8:00 am ET Executives Michael Charles A. Booth - Incyte Corp. Hervé Hoppenot - Incyte Corp. Barry P. Flannelly - Incyte Corp. Steven H. Stein - Incyte Corp. David W. Gryska - Incyte Corp. Reid M. Huber - Incyte...
Source: SeekingAlpha
Date: October, 30 2018 14:27
Incyte Corporation 2018 Q3 - Results - Earnings Call Slides
The following slide deck was published by Incyte Corporation in conjunction with their 2018 Q3 earnings Read more ...
Source: SeekingAlpha
Date: October, 30 2018 10:32


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on INCY.

About Incyte Corp. (NASDAQ: INCY)

Logo for Incyte Corp. (NASDAQ: INCY)

Not available


Contact Information



Current Management

  • Paul A. Friedman / CEO
  • Robert B. Stein / President
    • Robert B. Stein, PhD. MD, Director, is Chief Scientific Officer of Agenus Inc. Dr. Robert B. Stein leads Agenus Research, Preclinical Development and Translational Medicine functions. He helps shape clinical development strategy for vaccines and adjuvants. Additionally, he s leading integration of the Antibody acquisition, which includes the company s fully human antibody drug discovery and optimization technology platform, and portfolio of immune checkpoint antibody programs. Over his years of experience in the biopharmaceutical industry he played a pivotal role in bringing to the market Sustiva , Fablyn , Viviant , PanRetin , TargRetin , Promacta and Eliquis . Prior to joining Agenus he held executive management positions at Ligand Pharmaceuticals, DuPont Merck, Incyte Pharmaceuticals, Roche Palo Alto and KineMed. Dr. Stein began his career at Merck, Sharp and Dohme. He holds an MD and a PhD in Physiology amp Pharmacology from Duke University. Dr. Stein filed a personal voluntary bankruptcy petition under Chapter in August of and the bankruptcy was discharged in May .
  • Michael Lack / COO
  • John M. Vuko / CFO

Current Share Structure

  • Market Cap: $14,206,173,304 - 05/16/2018
  • Issue and Outstanding: 211,969,163 - 04/24/2018


Daily Technical Chart for (NASDAQ: INCY)

Daily Technical Chart for (NASDAQ: INCY)

Stay tuned for daily updates and more on (NASDAQ: INCY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: INCY)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in INCY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of INCY and does not buy, sell, or trade any shares of INCY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: